Product

LOXO-260

Aliases

LY3838915

2 clinical trials

3 indications

Indication

Indication

Non-Small Cell Lung

Indication

Clinical trial

A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors

Status: Active (not recruiting), Estimated PCD: 2025-06-01

Clinical trial

Expanded Access of LOXO-260 in Participants With RET Mutant or RET Fusion Tumors Refractory to Prior RET Selective TKI Treatment

Status: